Background: X-linked hypophosphatemia (XLH) is the most prevalent heritable form of rickets. It is a dominantly inherited disorder, characterized by renal phosphate wasting, abnormal vitamin D and PTH metabolism, and defective bone mineralization. Inactivating mutations in the gene encoding PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) have been found to be associated with XLH. Methods: We report about a 54-year-old male patient who exhibited the typical features of XLH, and in whom mutational analysis using PCR and sequencing was performed. Additionally, extensive laboratory and radiological investigations were carried out. Results: A 1-bp deletion in exon 2 of the PHEX gene was detected (177delC), which, to the best of our knowledge, has not been reported yet. This deletion results in a premature stop codon (C59X), suggesting a truncation of the PHEX protein. Furthermore, elevated FGF23 and PTH levels as well as an increased axial bone mineral density score were measured. Conclusions: We present a male patient with XLH, who harbors a novel mutation in the PHEX gene, which might be the cause for his disease. Our data support previous findings and therefore contribute to the decipherment of the pathogenetic pathways of XLH.

Keywords:
Hypophosphatemia, PHEX gene, XLH, Hypophosphatemic rickets
1.
McKusick VA: Mendelian Inheritance in Man: Catalogs of Human Genes and Genetic Disorders, ed 11. Baltimore, John Hopkins University Press, 1994.
2.
Reid IR, Murphy WA, Hardy DC, Teitelbaum SL, Bergfeld MA, Whyte MP: X-linked hypophosphatemia: skeletal mass in adults assessed by histomorphometry, computed tomography, and absorptiometry. Am J Med 1991;90:63–69.
3.
Oliveri MB, Cassinelli H, Bergada C, Mautalen CA: Bone mineral density of the spine and radius shaft in children with X-linked hypophosphatemic rickets. Bone Miner 1991;12:91–100.
4.
HYP Consortium: A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995;11:130–136.
5.
Sabbagh Y, Jones AO, Tenenhouse HS: PHEXdb, a locus-specific database for mutations causing X-linked hypophosphatemia. Hum Mutat 2000;16:1–6.
6.
Lo FS, Kuo MT, Wang CJ, Chang CH, Lee ZL, Van YH: Two novel PHEX mutations in Taiwanese patients with X-linked hypophosphatemic rickets. Nephron Physiol 2006;103:157–163.
7.
Christie PT, Harding B, Nesbit MA, Whyte MP, Thakker RV: X-linked hypophosphatemia attributable to pseudoexons of the PHEX gene. J Clin Endocrinol Metab 2001;86:3840–3844.
8.
Walton RJ, Bijvoet OL: Nomogram for derivation of renal threshold phosphate concentration. Lancet 1975;ii:309–310.
9.
ADHR Consortium: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345–348.
10.
Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE: A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 2005;90:2424–2427.
11.
Francis F, Strom TM, Hennig S, Boddrich A, Lorenz B, Brandau O, Mohnike KL, Cagnoli M, Steffens C, Klages S, Borzym K, Pohl T, Oudet C, Econs MJ, Rowe PS, Reinhardt R, Meitinger T, Lehrach H: Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets. Genome Res 1997;7:573–585.
12.
Holm IA, Nelson AE, Robinson BG, Mason RS, Marsh DJ, Cowell CT, Carpenter TO: Mutational analysis and genotype-phenotype correlation of the PHEX gene in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 2001;86:3889–3899.
13.
Shore RM, Langman CB, Poznanski AK: Lumbar and radial bone mineral density in children and adolescents with X-linked hypophosphatemia: evaluation with dual X-ray absorptiometry. Skeletal Radiol 2000;29:90–93.
14.
Rosenthall L: DEXA bone densitometry measurements in adults with X-linked hypophosphatemia. Clin Nucl Med 1993;18:564–566.
15.
Garn SM, Poznanski AK, Nagy JM: Bone measurement in the differential diagnosis of osteopenia and osteoporosis. Radiology 1971;100:509–518.
16.
Schmitt CP, Mehls O: The enigma of hyperparathyroidism in hypophosphatemic rickets. Pediatr Nephrol 2004;19:473–477.
17.
Carpenter TO, Mitnick MA, Ellison A, Smith C, Insogna KL: Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. J Clin Endocrinol Metab 1994;78:1378–1383.
18.
Blydt-Hansen TD, Tenenhouse HS, Goodyer P: PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia. Pediatr Nephrol 1999;13:607–611.
19.
Collins MT, Lindsay JR, Jain A, Kelly MH, Cutler CM, Weinstein LS, Liu J, Fedarko NS, Winer KK: Fibroblast growth factor-23 is regulated by 1α,25-dihydroxyvitamin D. J Bone Miner Res 2005;20:1944–1950.
20.
Nesbitt T, Drezner MK, Lobaugh B: Abnormal parathyroid hormone stimulation of 25-hydroxyvitamin D1 α-hydroxylase activity in the hypophosphatemic mouse. Evidence for a generalized defect of vitamin D metabolism. J Clin Invest 1986;77:181–187.
21.
Lobaugh B, Drezner MK: Abnormal regulation of renal 25-hydroxyvitamin D1 α-hydroxylase activity in the X-linked hypophosphatemic mouse. J Clin Invest 1983;71:400–403.
22.
Tenenhouse HS, Jones G: Abnormal regulation of renal vitamin D catabolism by dietary phosphate in murine X-linked hypophosphatemic rickets. J Clin Invest 1990;85:1450–1455.
23.
Tenenhouse HS, Yip A, Jones G: Increased renal catabolism of 1,25-dihydroxyvitamin D3 in murine X-linked hypophosphatemic rickets. J Clin Invest 1988;81:461–465.
24.
Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ: Sensitivity of fibroblast growth factor 23 measurements in tumor induced osteomalacia. J Clin Endocrinol Metab 2006;91:2055–2061.
25.
Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD: Pathogenic role of FGF23 in hyp mice. Am J Physiol Endocrinol Metab 2006;291:E38–E49.
26.
Berndt TJ, Schiavi S, Kumar R: ‘Phosphatonins’ and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 2005;289:F1170–F1182.
27.
Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC: FGF23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001;284:977–981.
28.
Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD: Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003;278:37419–37426.
29.
Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM: FGF23 is processed by proprotein convertases but not by PHEX. Bone 2004;35:455–462.
30.
Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H: Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656–1663.
31.
Bai X, Miao D, Li J, Goltzman D, Karaplis AC: Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004;145:5269–5279.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.